| P2093 | author name string | Rogier Q Hintzen | |
| | Peter A E Sillevis Smitt | |
| | Theo M Luider | |
| | Lennard J Dekker | |
| | Peter C Burgers | |
| | Christoph Stingl | |
| | Mark K Titulaer | |
| | Marcel P Stoop | |
| | Vaibhav Singh | |
| P2860 | cites work | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 |
| | Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice | Q24321396 |
| | Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry | Q28273166 |
| | CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis | Q28287666 |
| | Multiple sclerosis | Q28299151 |
| | Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap | Q29615742 |
| | Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. | Q52088310 |
| | Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. | Q52659421 |
| | Familial clustering of multiple sclerosis in a Dutch genetic isolate | Q57309148 |
| | Features of intrathecal immunoglobulins in patients with multiple sclerosis | Q59273810 |
| | Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein | Q69593309 |
| | Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis | Q81753382 |
| | Primary-progressive multiple sclerosis | Q31130362 |
| | The impact of blood contamination on the proteome of cerebrospinal fluid | Q31143697 |
| | Cerebrospinal fluid proteome profile in multiple sclerosis | Q33299647 |
| | A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases | Q33306704 |
| | Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. | Q33319975 |
| | Alteration of DBP levels in CSF of patients with MS by proteomics analysis | Q33370968 |
| | Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins | Q33401643 |
| | Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors | Q33410173 |
| | Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis | Q33481896 |
| | Vitamin D and multiple sclerosis | Q33809072 |
| | Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? | Q33864435 |
| | The role of notch in promoting glial and neural stem cell fates | Q34132317 |
| | Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis | Q34307160 |
| | Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3. | Q34455652 |
| | A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. | Q34648776 |
| | The complex role of vitamin D in autoimmune diseases | Q34656390 |
| | Which circulating level of 25-hydroxyvitamin D is appropriate? | Q35822352 |
| | Therapeutic potential of vitamin D-binding protein | Q35832200 |
| | Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. | Q35963620 |
| | New concepts on progressive multiple sclerosis | Q36815387 |
| | The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? | Q37427659 |
| | Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation | Q38362396 |
| | Jagged1 suppresses collagen-induced arthritis by indirectly providing a negative signal in CD8+ T cells. | Q39876476 |
| | CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis | Q39985745 |
| | Increased intrathecal production of apolipoprotein D in multiple sclerosis | Q43618799 |
| | Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans | Q43945155 |
| | Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. | Q48351890 |
| | Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. | Q48384914 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| | primary progressive multiple sclerosis | Q18553470 |
| | cerebrospinal fluid | Q54196 |
| P304 | page(s) | e12442 | |
| P577 | publication date | 2010-08-27 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis | |
| P478 | volume | 5 | |